{
  "id": 20309121,
  "title": "Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal",
  "url": "https://urgent.news/2026/11/16/lilly-pushes-buying-spree-beyond-32b-with-calytrix-deal",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T17:25:21.000Z",
  "source": {
    "name": "Bloomberg",
    "slug": "bloomberg",
    "url": "https://www.bloomberg.com/news/videos/2026-11-16/lilly-pushes-buying-spree-beyond-32b-with-calytrix-deal-video"
  },
  "original_language": "en",
  "account": null,
  "summary": "Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the biotech sector, how AI is playing…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}